Revivo has three candidate compounds under development for Alzheimer’s and other diseases of cognitive impairment. RIV-1061 has been evaluated in a prior Phase 1 study and is now returning to the clinic for development. Other compounds in the pipeline are targeted for Alzheimer’s disease or other neurodegenerative diseases leading to cognitive dysfunction.
revivo product pipeline
Cognitive Dysfunction Indications